The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Jörg Mahlich1 Janssen KK, Health Economics,Tokyo,Japan.;2 Heinrich-Heine University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE),Düsseldorf,Germany.Correspondence[email protected] [email protected]

Mona Groß2 Heinrich-Heine University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE),Düsseldorf,Germany.

Alexander Kuhlmann3 University of Hanover, Centre for Health Economics Research,Hanover,Germany.

Johannes Bogner4 Division of Infectious Diseases,Ludwig Maximilian University of Munich,Munich,Germany.

Hans Heiken5 Private Practice,Hanover,Germany.

Matthias Stoll6 Hannover Medical School (MHH), Centre for Internal Medicine,Hanover,Germany.

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Table 1 Variables

Table 2 Patient characteristics

Table 3 Multinomial logistic regression

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Figures & data

Table 1 Variables

Table 2 Patient characteristics

Table 3 Multinomial logistic regression

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date